INNOVIVA, INC. Amortization of Debt Discount (Premium)
INNOVIVA, INC. (INVA) reported Amortization of Debt Discount (Premium) of $2.00 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-10-27.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2021-10-27
- INNOVIVA, INC. amortization of debt discount (premium) for the quarter ending 2021-09-30 was $2.00M, a 9.25% increase year-over-year.
- INNOVIVA, INC. amortization of debt discount (premium) for the quarter ending 2020-09-30 was $1.83M.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 9 month |
|---|---|---|
| 2021-09-30 | $2.00M 10-Q · filed 2021-10-27 | $5.86M 10-Q · filed 2021-10-27 |
| 2020-09-30 | $1.83M 10-Q · filed 2021-10-27 | $5.36M 10-Q · filed 2021-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |